DrClaire Fletcher
Associate Professor of Molecular Oncology
Department of Surgery & Cancer - Faculty of Medicine
Orcid identifier0000-0003-2083-2798 (opens in a new tab)
- Associate Professor of Molecular OncologyDepartment of Surgery & Cancer - Faculty of Medicine
- 020 7594 2821 (Work)
- ICTEM building, Hammersmith Campus, United Kingdom
PROFESSIONAL ACTIVITIES
- GUEST LECTUREInvited Seminar - Royal College of Surgeons in Ireland1 Feb 2024
- EDITORIAL BOARDJournal of Endocrinology2 May 2022
- EDITORIAL BOARDJournal of Molecular Endocrinology2 May 2022
- GUEST LECTUREInvited seminar - Manchester University1 Jun 2021
- AWARDLeadership and Development Award2 Nov 2020
- EXTERNAL COMMITTEEScientific Committee2 Nov 2020 - 1 Nov 2022
- EXTERNAL COMMITTEEProstate Cancer Foundation Women's Networking Forum Organising Committee2 Mar 2020
- AWARDThe Rosetrees Trust PhD Student Prize 2014 - second place22 Oct 2015
- COLLABORATIONCentre for Atomic and Alternative Energies2 Dec 2013
- RESEARCH STUDENT SUPERVISIONAndrogen Receptor-Modulating MicroRNAs in Prostate Cancer Progression and Therapy
- COLLABORATIONCardiff University
- RESEARCH STUDENT SUPERVISIONCharacterisation of AR-modulatory microRNAs in Prostate Cancer
- RESEARCH STUDENT SUPERVISIONCRISPR screening to identify therapeutic vulnerabilities of drug-resistant prostate cancer cells
- COLLABORATIONJohns Hopkins School of Medicine
- COLLABORATIONMD Anderson Cancer Center, University of Texas
- RESEARCH STUDENT SUPERVISIONMicroRNA-346 as a Novel DNA-Damaging Therapeutic for Cancers of Unmet Need
- RESEARCH STUDENT SUPERVISIONMicroRNAs as treatment response biomarkers in prostate cancer
- RESEARCH STUDENT SUPERVISIONMiR-16-5p and miR-424-5p as regulators of proliferation and cell cycle progression in prostate cancer
- RESEARCH STUDENT SUPERVISIONModulation of miR-361-3p alters apoptosis in endocrine-resistant and -responsive breast cancer
- RESEARCH STUDENT SUPERVISIONSystematic Identification of MicroRNA Drivers of Resistance to Novel Therapeutics in Advanced Prostate Cancer – Exploitation as Stratification Biomarkers and Drug Targets